ImmunoPrecise Antibodies (IPA) Competitors

ImmunoPrecise Antibodies (NASDAQ:IPA) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.

Which has higher earnings and valuation, IPA or CTMX?

CytomX Therapeutics has higher revenue and earnings than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunoPrecise Antibodies	$24.00M	0.60	-$20.13M	-$1.16	-0.40
CytomX Therapeutics	$138.10M	0.44	-$570K	$0.38	1.99

Is IPA or CTMX more profitable?

CytomX Therapeutics has a net margin of 10.96% compared to ImmunoPrecise Antibodies' net margin of -114.50%. CytomX Therapeutics' return on equity of -41.47% beat ImmunoPrecise Antibodies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunoPrecise Antibodies	-114.50%	-73.74%	-42.68%
CytomX Therapeutics	10.96%	-41.47%	8.11%

Which has more volatility and risk, IPA or CTMX?

ImmunoPrecise Antibodies has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Do analysts recommend IPA or CTMX?

ImmunoPrecise Antibodies currently has a consensus price target of $4.00, suggesting a potential upside of 765.05%. CytomX Therapeutics has a consensus price target of $4.77, suggesting a potential upside of 530.20%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher possible upside, equities research analysts plainly believe ImmunoPrecise Antibodies is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunoPrecise Antibodies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
CytomX Therapeutics	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Does the media prefer IPA or CTMX?

In the previous week, CytomX Therapeutics had 5 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 7 mentions for CytomX Therapeutics and 2 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 0.96 beat CytomX Therapeutics' score of 0.71 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media.

Company	Overall Sentiment
ImmunoPrecise Antibodies	Positive
CytomX Therapeutics	Positive

Does the MarketBeat Community prefer IPA or CTMX?

CytomX Therapeutics received 360 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 93.75% of users gave ImmunoPrecise Antibodies an outperform vote while only 65.22% of users gave CytomX Therapeutics an outperform vote.

Company	Underperform	Outperform
ImmunoPrecise Antibodies	Outperform Votes 15 93.75%	Underperform Votes 1 6.25%
CytomX Therapeutics	Outperform Votes 375 65.22%	Underperform Votes 200 34.78%

Do institutionals and insiders hold more shares of IPA or CTMX?

6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CytomX Therapeutics beats ImmunoPrecise Antibodies on 13 of the 18 factors compared between the two stocks.